{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-24-010478","form_type":"8-K","ticker":"GKOS","cik":"0001192448","company_name":"GLAUKOS Corp","filed_at":"2024-07-31T23:59:59+00:00","discovered_at":"2026-05-14T18:03:12.359376+00:00","generated_at":"2026-05-31T14:16:45.917938+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Glaukos reports record Q2 sales $95.7M (+19% YoY), raises FY2024 guidance","bullets":["Record net sales of $95.7M, up 19% reported / 20% constant currency YoY.","Glaucoma segment sales $75.9M (+23% YoY); Corneal Health $19.8M (+7% YoY).","GAAP net loss $53.9M ($1.06 loss per share) vs $32.8M ($0.68) in Q2 2023.","Non-GAAP net loss $26.3M ($0.52 loss per share) improved from $26.6M ($0.55) prior year.","FY2024 net sales guidance raised to $370M–$376M from $357M–$365M."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-24-010478","json":"https://secwatch.observer/filing/0001558370-24-010478.json","markdown":"https://secwatch.observer/filing/0001558370-24-010478.md","text":"https://secwatch.observer/filing/0001558370-24-010478.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1192448/000155837024010478/0001558370-24-010478-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1192448/000155837024010478/gkos-20240731x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T14:16:45.917938+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}